Investment Thesis
Phio operates as an early-stage pharmaceutical company with minimal revenue ($231K) while burning $8M annually in operating cash flow, creating significant execution risk despite improving loss metrics YoY. With approximately 2.5 years of cash runway at current burn rates, the company must demonstrate near-term revenue acceleration or cost reduction to achieve profitability before capital depletion.
Strengths
- Exceptional balance sheet strength with $21M cash, zero long-term debt, and $1.3M total liabilities
- Outstanding liquidity position with 17.81x current ratio providing substantial operational flexibility
- Improving loss trajectory with net loss declining 21.7% YoY and EPS improving 80.6% YoY
Risks
- Deeply unprofitable operations with operating margin of -3991.3% and net margin of -3765.4% indicating massive operational losses
- Negative operating cash flow of -$8M annually with revenue of only $231K suggesting pre-commercial or failed commercialization stage
- Limited cash runway of approximately 2.5 years at current burn rate with unproven path to profitability or financing capability
Key Metrics to Watch
- Revenue growth trajectory and timeline to commercial product revenue generation
- Operating cash burn rate and trend in cash consumption relative to clinical milestones
- Monthly cash burn rate reduction and achievement of non-dilutive funding sources
Financial Metrics
Revenue
231.0K
Net Income
-8.7M
EPS (Diluted)
$-0.86
Free Cash Flow
-8.0M
Total Assets
21.5M
Cash
21.0M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-3,991.3%
Net Margin
-3,765.4%
ROE
-43.2%
ROA
-40.5%
FCF Margin
-3,459.3%
Balance Sheet & Liquidity
Current Ratio
17.81x
Quick Ratio
17.81x
Debt/Equity
0.00x
Debt/Assets
6.2%
Interest Coverage
N/A
Long-term Debt
0.0
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-14T07:15:26.165604 |
Data as of: 2025-12-31 |
Powered by Claude AI